Favaretto, Adolfo, Francesco Grossi, Alessandro Morabito, and Roberto Ravasio. 2017. “Costs of Adverse Events Associated With Afatinib, Erlotinib, and Gefitinib First-Line Therapies in Advanced Non-Small-Cell Lung Cancer Harboring EGFR-Activating Mutations: Il Costo Degli Eventi Avversi Associati Ad Afatinib, Erlotinib E Gefitinib Nel Trattamento Del Tumore Del Polmone Non a Piccole Cellule Con Mutazione EGFR”. Global and Regional Health Technology Assessment 4 (1):187-96. https://doi.org/10.33393/grhta.2017.394.